Advertisement

International Journal of Clinical Oncology

, Volume 23, Issue 3, pp 452–457 | Cite as

The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations

  • Yuri Taniguchi
  • Yoko Matsumoto
  • Ryutaro Furukawa
  • Sayaka Ohara
  • Kazuhiro Usui
Original Article
  • 205 Downloads

Abstract

Background

The process of selecting patients on the basis of epidermal growth factor receptor (EGFR) mutations would likely result in a patient population with greater sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, EGFR mutation status is not routinely examined in patients with squamous cell lung cancer (Sq) because of the low incidence of EGFR mutations and the poor clinical response to EGFR-TKIs.

Methods

We retrospectively reviewed the clinical features of patients at our hospital with Sq who carried EGFR-TKI-sensitive EGFR mutations and assessed their responses to EGFR-TKIs.

Results

EGFR mutation status was tested in 23 of 441 patients with Sq (5.2%) admitted to our hospital during the study period. An EGFR mutation (exon 19 deletion 3, L858R 2) was identified in five of the 23 patients (21.7%), all of whom were female never-smokers. Of these five patients, four (4/9; 44.4%) were in the normal lung group, one (1/12; 8.3%) was in the emphysematous lung group, and none (0/2; 0%) in the fibrotic lung group. Two of these five patients with the EGFR mutation received gefitinib and two received afatinib. Although the two patients who were treated with gefitinib did not respond well to treatment (stable disease, 1 patient; progressive disease, 1 patient), the two patients who were treated with afatinib showed a good response (partial response, 2 patients).

Conclusion

The administration of afatinib to Sq patients after selecting patients using the EGFR mutation test based on their underlying pulmonary disease and smoking status would likely result in a population with a greater sensitivity to afatinib.

Keywords

Squamous cell lung cancer EGFR-TKI-sensitive EGFR mutation Afatinib 

Notes

Compliance with ethical standards

The study protocol was reviewed and approved by the Ethics Committee of NTT Medical Center Tokyo.

Conflict of interest

The authors declare no conflicts of interest in association with the present study.

References

  1. 1.
    Center for Cancer Control and Information Services (2014) Cancer statistics in Japan 2014. Center for Cancer Control and Information Services, National Cancer Center Japan, Tokyo. https://ganjoho.jp/en/professional/statistics/brochure/2014_en.html
  2. 2.
    Cheng TY, Cramb SM, Baade PD et al (2016) The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 11(10):1653–1671CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Youlden DR, Cramb SM, Baade PD (2008) The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 3:819–831CrossRefPubMedGoogle Scholar
  4. 4.
    Langer CJ, Obasaju C, Bunn P et al (2016) Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment. J Thorac Oncol 11(12):2066–2081CrossRefPubMedGoogle Scholar
  5. 5.
    Hirsh V (2017) New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 10:2513–2526CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yang JC, Wu YL, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151CrossRefPubMedGoogle Scholar
  7. 7.
    Paz-Ares L, Tan EH, O’Byrne K et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28(2):270–277CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Soria JC, Felip E, Cobo M, LUX-Lung 8 Investigators et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897–907CrossRefPubMedGoogle Scholar
  9. 9.
    Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519–525CrossRefGoogle Scholar
  10. 10.
    Liam CK, Leow HR, Pang YK (2013) EGFR mutation testing for squamous cell lung carcinoma. J Thorac Oncol 8(12):e114CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang Q, Zhu L, Zhang J (2015) Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients. BMC Cancer 15:88CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Shukuya T, Takahashi T, Kaira R et al (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 102(5):1032–1037CrossRefPubMedGoogle Scholar
  13. 13.
    Fang W, Zhang J, Liang W et al (2013) Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis 5(5):585–592PubMedPubMedCentralGoogle Scholar
  14. 14.
    Xu J, Chu T, Jin B et al (2016) Epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell lung cancer. Clin Lung Cancer 17(4):309–314CrossRefPubMedGoogle Scholar
  15. 15.
    Joshi A, Zanwar S, Noronha V et al (2017) EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther 10:1859–1863CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Liu Y, Zhang Y, Zhang L et al (2017) Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. Oncotarget 8(30):49680–49688Google Scholar
  17. 17.
    Usui K, Tanai C, Tanaka Y et al (2011) The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology 16(2):326–331CrossRefPubMedGoogle Scholar
  18. 18.
    Usui K, Ushijima T, Tanaka Y et al (2011) The frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases. Pulm Med 290132:2011Google Scholar
  19. 19.
    Sutani A, Nagai Y, Udagawa K et al (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95(11):1483–1489CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350CrossRefPubMedGoogle Scholar
  22. 22.
    Felip E, Soria JC, Cobo M et al (2017) Second-line afatinib versus erlotinib for patients with squamous cell carcinoma of the lung (Lux-Lung 8): analysis of tumor and serum biomarkers. J Thorac Oncol 12(1) [Suppl]:S1186–S118Google Scholar
  23. 23.
    Goss G, Felip E, Cobo M et al (2017) Impact of EGFR mutations on clinical outcomes in afatinib- or erlotinib- treated patients with SCC of the lung. J Thorac Oncol 12(11) [Suppl 2]:S2217–S2218Google Scholar
  24. 24.
    Gadgeel S, Goss G, Soria JC et al (2017) Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 109:101–108CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2018

Authors and Affiliations

  • Yuri Taniguchi
    • 1
  • Yoko Matsumoto
    • 1
  • Ryutaro Furukawa
    • 1
  • Sayaka Ohara
    • 1
  • Kazuhiro Usui
    • 1
  1. 1.Division of RespirologyNTT Medical Center TokyoTokyoJapan

Personalised recommendations